



Via E-Mail: Phil Early request-850377a219b921@whatdotheyknow.com Trust Headquarters Lincoln County Hospital Greetwell Road Lincoln LN2 5QY

Ref - 003/22

19 May 2022

Tel: 01522 573977 Email: foi@ulh.nhs.uk www.ulh.nhs.uk

Dear Mr Early

We would like to apologise for the delay in responding to your freedom of information request dated 1 April 2022 regarding breast cancer treatment. The questions you raised along with their answers can be found below:

I would like to please request the following information with regards to Breast Cancer Treatment. The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

- Abemaciclib (Verzenios) + aromatase inhibitor* 16
- Abemaciclib (Verzenios) + Fulvestrant (Faslodex) 16
- Alpelisib (Pigray) + Fulvestrant (Faslodex) 0
- Atezolizumab (Tecentriq)** Less than 5
- Bevacizumab (Avastin) 0
- Eribulin (Halaven) Less than 5
- Everolimus (Afinitor) + Exemestane 0
- Fulvestrant (Faslodex) as a single agent 6
- Gemcitabine + paclitaxel 0
- Herceptin (Trastuzumab) + paclitaxel Less than 5
- Herceptin (Trastuzumab) as a single agent Less than 5
- Lapatinib (Tyverb) 0
- Neratinib (Nerlynx) 0
- Olaparib (Lynparza) 0
- Palbociclib (Ibrance) + aromatase inhibitor* 25
- Palbociclib (Ibrance) + Fulvestrant (Faslodex) Less than 5
- Pertuzumab (Perjeta) + Trastuzumab + Docetaxel 23
- Ribociclib (Kisgali) + aromatase inhibitor* Less than 5
- Ribociclib (Kisqali) + Fulvestrant (Faslodex) 0
- Talazoparib (Talzenna) 0
- Trastuzumab emtansine (Kadcyla) 6
- Other active systemic anti-cancer therapy** 45

^{*}aromatase inhibitor e.g. Anastrazole, Exemestane or Letrozole

^{**}e.g. Docetaxel, Vinorelbine or Capecitabine as a single agent

Q2. For the above patients, how many of these received their first ever dose for each product line?

- Abemaciclib (Verzenios) + aromatase inhibitor* 5
- Abemaciclib (Verzenios) + Fulvestrant (Faslodex) Less than 5
- Alpelisib (Piqray) + Fulvestrant (Faslodex) 0
- Atezolizumab (Tecentriq)** Less than 5
- Bevacizumab (Avastin) 0
- Eribulin (Halaven) Less than 5
- Everolimus (Afinitor) + Exemestane 0
- Fulvestrant (Faslodex) as a single agent 0
- Gemcitabine + Paclitaxel 0
- Herceptin (Trastuzumab) + Paclitaxel 0
- Herceptin (Trastuzumab) as a single agent Less than 5
- Lapatinib (Tyverb) 0
- Neratinib (Nerlynx) 0
- Olaparib (Lynparza) 0
- Palbociclib (Ibrance) + Aromatase Inhibitor* 0
- Palbociclib (Ibrance) + Fulvestrant (Faslodex) 0
- Pertuzumab (Perjeta) + Trastuzumab + Docetaxel Less than 5
- Ribociclib (Kisqali) + Aromatase Inhibitor* 0
- Ribociclib (Kisqali) + Fulvestrant (Faslodex) 0
- Talazoparib (Talzenna) 0
- Trastuzumab Emtansine (Kadcyla) Less than 5
- Other active systemic anti-cancer therapy** 21

I trust that this information answers your request; however, if you are unhappy with the service you have received and wish to make a complaint or request a review of our response, you should write to the Chief Executive at the address given above.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision. Generally, their office cannot make a decision unless you have exhausted the complaints procedure provided by United Lincolnshire Hospitals NHS Trust.

The Information Commissioner can be contacted at: The Information Commissioners Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Yours sincerely

Jayne Warner Trust Secretary

^{*}aromatase inhibitor e.g. Anastrazole, Exemestane or Letrozole

^{**}e.g. docetaxel, Vinorelbine or Capecitabine as a single agent